RVXOldtimer ... agreed, and additionally, "if" that were the case ... given the safety profile, doctors could still

1) prescribe apabetalone with Lipitor anyway for whatever smaller benefit has shown to be provided with the combination (if staying on Lipitor is required for a unique patient),

2) switch the patient to Crestor/generic from Lipitor if there are no patient issues with doing this for a unique patient, although possibly unlikely if Lipitor is doing good things for that patient,

3) increase Crestor/generic market share by putting more patients on Crestor/generic as new starts due to combined benefit with apabetalone .....

As long as the safety profile is solid, and we understand why apabetalone is better in different combinations, not a problem right, prescribe according to patient needs. May lose a portion of the current Lipitor specific market, but that is trending/migrating away from Lipitor anyway.